Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a ...

In addition, Jefferies expects Tata Motors to see a tough year ahead with the demand for Indian trucks growing soft and the ...

Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share ...